a nonsignificant trendP = 0.06
CGM demonstrated a nonsignificant trend toward reduced incidence of LGA (RR 0.81, 95% CI 0.65 to 1.01, P = 0.06, I2 = 31%) and neonatal hypoglycemia (RR 0.85, 95% CI 0.70 to 1.03, P = 0.10, I2 = 0%).
CGM demonstrated a nonsignificant trend toward reduced incidence of LGA (RR 0.81, 95% CI 0.65 to 1.01, P = 0.06, I2 = 31%) and neonatal hypoglycemia (RR 0.85, 95% CI 0.70 to 1.03, P = 0.10, I2 = 0%).
Pooled results showed a trend toward reduced neonatal hypoglycemia in the CGM group compared with the SMBG group (RR 0.85, 95% CI 0.70 to 1.03, P = 0.10, I2 = 0%, Figure 4A ).
CGM may reduce the risk of LGA and neonatal hypoglycemia, although the beneficial effects did not reach statistical significance.